NCT05431387 Phase 2 Completed
A Study of Cytisinicline for Vaping Cessation in Adult Smokers Study sponsor: Achieve Life Sciences
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2023-02-28 Actual
Enrollment · participants 160 Actual
Source updated 2026-01-14 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2026-01-14 · 1 field changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Proportion of Participants With Vaping Abstinence During Weeks 9 to 12
+ Updated value measure: Percentage of Participants With Vaping Abstinence From Week 9 to 12
The saved outcome text may be shortened. Check the source for full wording.
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial